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Liver cirrhosis (LC) can lead to a clinical state of liver failure, which can exacerbate through the course of the disease. New
therapies aimed to control the diverse etiologies are now more eﬀective, although the disease may result in advanced stages
of liver failure, where liver transplantation (LT) remains the most eﬀective treatment. The extended lifespan of these patients
and the extended possibilities of liver support devices make their admission to an intensive care unit (ICU) more probable. In
this paper the LC is approached from the point of view of the pathophysiological alterations present in LC patients previous
to ICU admission, particularly cardiovascular, but also renal, coagulopathic, and encephalopathic. Infections and available liver
detoxiﬁcations devices also deserve mentioning. We intend to contribute towards ICU physician readiness to the care for this
particular type of patients, possibly in dedicated ICUs.
1.Introduction
Liver cirrhosis (LC) is a late stage of progressive hepatic
ﬁbrosis is characterized by distortion of the architecture and
formation of regenerative nodules and diﬀerent degrees of
liver function impairment; these patients are prone to a
variety of complications reducing life expectancy markedly
[1].
The World Health Organization (WHO) indicates that
10% of the world population has chronic liver disease; this
represents approximately 500 million people with 20 million
people worldwide having liver cirrhosis and/or liver cancer.
Two million people worldwide die each year from hepatic
failure. In the United States the number of discharges with
chronic liver disease or cirrhosis as the ﬁrs t-listed diagnosis
totaled 112,000 patients in 2007 and 29,165 deaths (9.7
deaths/10000 population) [2].
Decompensate end-stage liver disease (ESLD), acute-on-
chronic liver failure, and acute liver failure (ALF) are critical
situations, which lead to hepatic encephalopathy and mul-
tiple organ failure (MOF) [3]. These critical situations may
require admission and end-organ support in an intensive
care unit (ICU). The rationales for patient admission are
recoveryofliverfunctionandtoprovideaneﬀectivebridging
to liver transplantation (LT), the most eﬀective therapy for
the failing liver.
Liver transplantation is hampered by the shortage of
organ donors, resulting in a great incidence of patients with
ALF who die while awaiting LT [4, 5]. The availability of
liver support therapies may alter the future perspective of
these patients, which can be admitted more often to the
ICU. Several liver support devices are available and may
be nonbiological (MARS, Gambro Inc.; Prometheus device,
Fresenius Medical Care; SEPET, Selective Plasma Exchange2 Critical Care Research and Practice
Therapy from Arbios Systems, Inc.) or may have a biological
component (bioartiﬁcial liver, BAL).
The authors intend to perform a comprehensive review
of the physiopathology of the patient with LC, focusing on
critical care in light of the new liver support therapies.
2. The Impact of Cirrhosison
Cardio-CirculatorySystem
Cardiovascular complications in the patient with LC are a
major cause of perioperative mortality and graft loss [6].
The main cardiovascular disorders of LC are portal
hypertension and a permanent state of hyperdynamic circu-
lation. The increased blood ﬂow in the splanchnic bed exac-
erbates the portal hypertension and consequently increases
the incidence of esophageal varices, variceal bleeding, and
ascites. In the pathophysiology of ascites the peripheral
vasodilatation contributes to decreasing the eﬀective circu-
lating volume, which is sensed by the kidney as hypovolemia,
leading to salt and water retention. In more severe cases, this
leads to severe renal vasoconstriction and a decline in renal
function, which characterizes the hepatorenal syndrome
(HRS).
The hallmark of this state of hyperdynamic circulation
is an increase in heart rate (HR), cardiac output (CO), and
left ventricular ejection fraction (LVEF) and a decrease in
systemic vascular resistance (SVR), mean arterial pressure
(MAP), and blood vessel contraction. Multiple pathophysio-
logicalmechanismshavebeenproposedtoexplainthesecon-
ditions (neurogenic, humoral, and vascular dysregulation)
and are summarized in Table 1 [7]. Although the etiology
is remarkably diﬀerent, this hemodynamic pattern resembles
that of sepsis patients [8]. It has been reported that arterial
vasodilatation activates the sympathetic nervous system and
the renin-angiotensin-aldosterone system, resulting in a
tachycardia response. Blood volume is decreased at a central
level (heart, lungs, and great vessels) and increased in the
periphery (mainly the splanchnic circulation) [9]. With the
evolution of the illness, there are other precipitating fac-
tors of clinical worsening such as autonomic dysfunction,
desensitization of myocardial beta-adrenergic receptors [10,
11], conditioning hyporesponsiveness to treatment with
vasoactive, and nitration of cardiac proteins [12].
In an experimental model in rats with induced portal
hypertension, reductions in myocardial contractility and
beta-adrenergic response were observed and these ﬁndings
wereassociatedwithapossiblealteredexcitation-contraction
coupling, decreased sarcolemma L-type calcium channel
density, and reduced calcium in the sarcoplasmic reticulum.
Portal hypertension also induces portosystemic collat-
erals that drive gut-derived substances directly to systemic
circulation without hepatic clearance. Nitric oxide (NO)
is overproduced in LC and is increased in peripheral cir-
culation, which results in peripheral vasodilatation and
secondary to architectural and vasoactive humoral changes
i nt h el i v e r .T h e r ei sa ni n c r e a s ei nv a s o a c t i v em o l e c u l e ss u c h
as angiotensin II, endothelin 1, and cysteinyl leukotriene
associated with decreased intrahepatic NO production. The
Table 1: The pathophysiology of cardiovascular abnormalities.
Attenuated systolic and diastolic response to stress stimuli
Structural and histological changes in cardiac chambers
Electrophysiological abnormalities
Increased serum markers of cardiac stress
Altered function of β-adrenergic and muscarinic receptors:
(i) Reduced receptor density in cirrhotic patients and animal
model
(ii) Enhanced muscarinic: contributing to the negative inotropic
eﬀect on the myocardium
(iii) Altered membrane ﬂuidity: these changes have a profound
eﬀect on the β- adrenoceptor function that includes impairing
the receptor-ligand interaction and aﬀects the function of
membrane-bound ion channels (Ca++ and K+)
NO, carbon monoxide, and endocannabinoids exerts a negative
eﬀect on cardiac contractility
net result is a progressive increase in intrahepatic vascular
resistance and portal hypertension [13].
B-type natriuretic peptide (BNP) concentrations are
higher in cirrhosis. Pimenta et al. in a study that included 83
patients hospitalized with decompensated cirrhosis observed
that BNP level in cirrhosis reﬂects cardiac systolic function
and is an independent predictor of medium-term survival
in advanced cirrhosis. Median BNP level was 130.3 (65.2–
363.3pg/mL). BNP levels above the median were associated
with an increased occurrence of death within 6 months of
discharge [14, 15].
With regard to pulmonary circulation vascular dilatation
occurs, as well as, intrapulmonary shunts and low pul-
monary vascular resistance. The alveolar-capillary disequi-
librium hypothesis states that pulmonary vascular dilatation
and the intrapulmonary shunts in patients with LC are the
leading contributors to hypoxemia in advanced liver disease.
The low pulmonary vascular resistance leads to a reduction
in the intrapulmonary transit time and subsequently a
decreased oxygen diﬀusion across the dilated pulmonary
vessels. Another pattern of intrapulmonary vascular dilation
is characterized by localized dilatation of parts of the pul-
monary vasculature and associated with large arteriovenous
shunting, with poor response to oxygen supplementation
[16–18].
3. CirrhoticCardiomyopathy
Although the cardiovascular impact of the LC is of common
knowledge for almost 60 years [19] ,i t st r u ep r e v a l e n c e
remains unknown since it is not observed in all patients
with LC, only in those with more advanced disease [20]. The
recognition of a distinctive non-alcohol-related cardiomy-
opathy in LC is recent. Cirrhotic cardiomyopathy (CCM)
is the term used to describe a group of features indicative
of abnormal cardiac performance in cirrhotic patients that
seems to be an independent entity, diﬀerent from ethanol-
induced cardiomyopathy.
Little data is available on myocardial changes due to
LC. The course of progressive damage to the cardiovascularCritical Care Research and Practice 3
system can be silent and precipitate after stress maneuvers,
making both diagnosis and treatment, in most cases, late and
diﬃcult.Onlyscatteredclinicalstudieshavespeciﬁcallystud-
ied the features of the CCM, this could justify why there are
no widely accepted diagnostic criteria. A working deﬁnition
was proposed in the World Congress of Gastroenterology in
Montreal (Canada) in 2005 and is detailed in Table 2.
If the CCM is not diagnosed in a timely manner or is
treated improperly, it can lead to heart failure [21]. Rates
of pulmonary edema rise up to 50% and hemodynamically
signiﬁcant arrhythmias have been reported in 27% of
patients in the perioperative phase of LT. Fouad et al. [22]
studied 197 post-LT patients and found prevalence close to
50% of cardiac decompensation, being the main cause of
death in these patients.
The histopathology of CCM is nonspeciﬁc. The autopsy
ﬁndings include increased ventricular volumes and mass,
hypertrophy of cardiomyocytes, interstitial and intracellular
edema, and signs of cellular injury; also, the left ventricle
(LV) is thickened and less compliant. These ﬁndings are
more evident in patients with ascites [23], and they are more
frequent in the LV than in the right ventricle [24].
One of the factors thought likely to participate in the
pathogenesis of CCM is the increase in intra-abdominal
pressure in cirrhotic patients. However, as CCM has been
described in patients without ascites, it appears that no
mechanical factors would cause progressive cardiac deteri-
oration (nitric oxide, TNFα, bile acids, and beta-adrenergic
receptor dysfunction).
LV systolic function has been the most studied feature
of CCM, which in particular is normal at rest but, in sit-
uations of physical stress (surgery, infection, and bleeding,
exercise), psychological or pharmacological (dobutamine,
sodium load) is aﬀected [25]. In CCM the ejective period is
shortened and preejective time is lengthened [26]. Diastolic
dysfunction occurs due to a defect in ventricular compliance
that alters its physiological ﬁlling, and yet not demonstrated
in cirrhotic patients, some authors suggest its presence in
all cases of CCM and the echocardiography ﬁnding of a
pathological mitral E/A ratio may be suﬃcient for diagnosis
(Figure 1)[ 27]. Nonetheless, it has been described in most
cirrhotic patients without cardiomyopathy. If diastolic dys-
function is present, it will be more deteriorated after LT,
especially in the ﬁrst 3 months [28]. It appears to be more
common in patients with ascites, and it is also demonstrated
that paracentesis improves diastolic and systolic functions
[29].
Electrophysiological changes have been described in
patients with cirrhosis such as rhythm disturbances, QT pro-
longation, ventricular dyssynchrony, and chronotropic in-
competence. Rhythm disturbances more frequently reported
are atrial ﬁbrillation, atrial ﬂutter and extrasystoles; these
may be due to changes in the permeability of the cell
plasma membrane [30]. QTc prolongation is due to changes
in myocardial repolarization and can lead to ventricular
arrhythmias such as Torsade de Pointes, ventricular tachy-
cardia, ventricular ﬁbrillation, and even sudden death [31].
LT can improve the QTc interval of patients who have it
prolonged [32].
Table 2: Deﬁnition of cirrhotic cardiomyopathy.
Systolic dysfunction
(i) Blunted increase in cardiac output with
stress
(ii) Resting LVEF <55%
Diastolic dysfunction
(i) E/A ratio <1
(ii) Prolonged DT (>200msec)
(iii) Prolonged IVRT (>80msec)
Supportive criteria
(i) Electrophysiological abnormalities
(ii) Altered chronotropic response
(iii) Electromechanical dyssynchrony
(iv) Prolonged QTc
(v) Enlarged LA
(vi) Increased cardiac mass
(vii) Increased BNP/proBNP
(viii) Increased troponin I
Figure 1: Diastolic dysfunction in a cirrhotic patient diagnosed
during pretransplantation echocardiographic study (E/A ratio <
0.8, DTE > 240).
Chronotropic incompetence is associated with increased
risk of perioperative complications and can be deﬁned as
the failure to achieve 82% of the predicted heart rate after
dobutamine echocardiography. It was associated with an
increased risk of almost 4 times in the ﬁrst months after LT
(22% versus 6%) [33, 34].
Limited studies suggested that, in an earlier stage of
CCM, mechanical dyssynchrony preceded LV dysfunction;
in fact, mechanical dyssynchrony is one of the diagnostic
criteria in the working deﬁnition of CCM. Recently, Aaroudi
et al. [35] performed a study with 178 patients with LC
who underwent stress-gated Tc-99m myocardial perfusion
imaging and found no diﬀerences in dyssynchrony indexes
between survivors and nonsurvivors, concluding that in
patients with LC there is insuﬃcient evidence of a higher
incidence of LV dyssynchrony.
The transjugular portosystemic shunt (TIPS) produces
an acute increase in preload by shifting traﬃc from the
portal vein circulation to the systemic circulation, leading
to a worsening of the hyperdynamic state by increasing CO,
biatrial end-diastolic volume, and a decrease in SVR. It is
estimated that 1% of cirrhotic patients without cardiac his-
tory developed heart failure after TIPS [36]. With the TIPS,4 Critical Care Research and Practice
the central ﬁlling pressures increase more than 2 times. The
stroke volume index increased up to 20% immediately [37].
Within two years, both CO and S VR showed a trend toward
normalization, together with mild LV hypertrophy. These
consequences are responsible for an increased probability of
death in patients with CCM immediately after TIPS [38].
Another trigger for decompensation of CCM is LT. It is
the third leading cause of death after rejection and infection
[39], 47% of patients have radiographic acute pulmonary
edema immediately after LT [40], and 3% developed new
dilated cardiomyopathy in the ﬁrst 6 months [41].
Several studies support the correlation between CCM
andelevatedatrialnatriureticpeptide(ANP),BNP,pro-BNP,
and troponin I, which could be used in screening. It seems
that ANP is less speciﬁc since its alteration is related to atrial
distension or distortion that can sometimes exist alongside
eﬀective hypovolemia [42]. Several studies have shown that
when pro-BNP and BNP were elevated, these were related to
the severity of cirrhosis, myocardial dysfunction, myocardial
hypertrophy, and QT prolongation [43, 44]. Troponin I is
a key parameter for the diagnosis of myocardial ischemia,
which has proved to be useful for diagnosing other entities
suchassepsis-inducedmyocardialdysfunction,hypertrophic
cardiomyopathy, and LC. Pateron et al. [45] showed that
patients with LC, who had elevated serum troponin I,
correlated with lower LV stroke volume and mass index.
Risk assessment with ECG, coronary angiography, and
myocardial perfusion scintigraphy has failed to predict a
perioperative CCM [46, 47].
The most common way to study the LV systolic function
is using two-dimensional echocardiography. For the analysis
of diastolic function, the mitral E/A ratio has been analyzed
in most reported studies of CCM, concluding that a ratio
≤1 is associated with increased mortality risk. A mitral E/A
ratio ≤1 is present in 50–70% of patients with ESLD, being
more evident with the disease progression (MELD ≥ 20) and
lowest in patients with ascites [48, 49]. However, the mitral
E/A ratio is also preload dependent [50] and does not allow
us to diagnose a pseudonormal pattern (grade II diastolic
dysfunction), so the real incidence of diastolic dysfunction
in patients with LC is underestimated. Recent studies using
new echocardiographic technologies such as Doppler tissue
imaging (DTI) are promising [51]. Kazankov et al. [52]
studied LV systolic and diastolic functions using DTI at rest
in44cirrhoticpatientswithoutpreviousknownheartdisease
and simultaneously analyzed tissue velocities and strain
rate in various segments of the LV in the same cineloop.
They noted that all patients had systolic dysfunction and
54% had diastolic dysfunction (25% impaired diastolic
relaxation pattern, 27% pseudonormal ﬁlling pattern, and
2% restrictive ﬁlling pattern) at rest. These ﬁndings suggest
that the current characterization of the CCM is doubtful,
further studies are needed in this ﬁeld. Advanced methods
suchasechocardiographywithDTIandspeckletrackingmay
become the gold standard for CCM diagnosis.
Unfortunately there is no speciﬁc treatment for CCM
[53]. Few treatments have been proposed to date and many
of them are simply experimental. The clinical management
of patients with CCM includes supportive measures.
Accumulating evidence suggests the use of cardiopro-
tective drugs, such as beta-blockers, statins, angiotensin-
convertingenzymeinhibitors,orantialdosterone agents[54–
58].
Albumin dialysis using the molecular adsorbent recircu-
lating system (MARS) has been shown to improve hemody-
namicstatusofpatientswithESLD.Nonetheless,theseeﬀects
disappeared four days after cessation of MARS. [59, 60].
4.PortopulmonaryHypertension
Portopulmonary hypertension (PoH) is usually deﬁned
using parameters obtained by right heart catheterization
in patients with PoH. These include elevated pulmonary
mean artery pressure (>2 5m m H ga tr e s to r>30mmHg with
exercise, or pulmonary artery systolic pressure >45mmHg),
increased pulmonary vascular resistance (PVR > 240
dyness/cm5), normal pulmonary capillary wedged pressure
(PCWP <15mmHg), or transpulmonary gradient (the dif-
ference between mean pulmonary artery pressure, MPAP,
and PCWP) >12mmHg.
PoPH is a relatively rare condition, aﬀecting 5% to 6%
of LC patients [61] and commonly observed among patients
with end-stage liver disease, biliary atresia, portal vein
thrombosis, Budd-Chiari syndrome, and schistosomiasis.
Pathologicalandpathophysiologicalfeaturesincludevas-
cular alterations, such as intimal ﬁbrosis, increased medial
thickness, pulmonary arteriolar occlusion, in situ thrombo-
sis,andplexiformlesionsresultingfromintramuralendothe-
lialization of microaneurysms; dysregulation of vascular,
proliferative, and angiogenic mediators; hyperdynamic cir-
culation leading to increased shear stress within pulmonary
vasculature followed by a neurohumoral response charac-
terized by elevated levels of endothelin-1 (ET-1); the excess
of ET-1 acting through ETA receptor, inducing pulmonary
vasoconstriction, smooth muscle proliferation, and ﬁbrosis;
upregulation of other neurohumoral mediators (thrombox-
ane and interleukin-6); decreased synthesis, in the pul-
monary vasculature, of NO due to decreased levels of nitric
oxide synthase [13, 14, 62].
Early stage of PoPH is generally asymptomatic. With
advancing disease the dyspnea with exertion is the most
frequent presenting symptom (81%); other symptoms, such
as syncope, chest pain, and fatigue are seen in a third of the
patients. PoPHcanaﬀectpatients atanyageand occasionally
occur in noncirrhotic patients with PoH and have been
also reported in mild liver disease. The disease staging is
presented in Table 3.
A carefully evaluation must be made to exclude other
potential causes of pulmonary hypertension (Table 4). Chest
radiography may be normal in the early stages but in more
advanced stages can show prominent main and central pul-
monaryvessels,sharplyperipheralvessels,andrightventricle
enlargement. Computed tomography chest scan shows an
increased pulmonary artery diameter. Lung perfusion testing
may also show multiple patchy defects. Arterial blood gases
show a chronic respiratory alkalosis and impaired arterial
oxygenation.Critical Care Research and Practice 5
Table 3: Stages of portopulmonary hypertension.
Stage MPAP
(mmHg) Regarding liver transplantation
Mild 25–35 No added risk of perioperative morbidity
or mortality
Moderate 35–44
High risk of perioperative morbidity and
mortality; considering vasodilator
therapy; relative contraindication for
liver transplantation
Severe >45 Absolute contraindication for liver
transplantation
Table 4: Diagnosis of pulmonary hypertension.
Idiopathic pulmonary arterial hypertension
Pulmonary arterial hypertension associated with:
(i) Connective tissue diseases
(ii) Congenital heart diseases
(iii) Portopulmonary hypertension
(iv) HIV infection
Left heart disease:
(i) Systolic and diastolic dysfunction
(ii) Valvular heart disease
Primary lung diseases and/or chronic hypoxia
(i) Chronic obstructive pulmonary disease
(ii) Interstitial lung disease
(iii) Sleep-disordered breathing
Chronic thromboembolism
Transthoracic echocardiography using Doppler estima-
tion of pulmonary artery systolic pressure is the screening
tool of choice, using a threshold cut-oﬀ value of 30mmHg;
the sensitivity is 100% and the speciﬁcity is 96%.
Regarding LC moderate to severe PoPH confers a high
riskofcardiopulmonary-relatedmortality[63];basedonthis
many centers use pretransplantation evaluation of MPAP
as shown in the Figure 2. Current treatment options are
presented in Table 5.
5. Hepatopulmonary Syndrome
Clinical presentation is characterized by dyspnea of insidious
onset associated with cyanosis in 90% of all cases, platypnea,
and orthodeoxia. The presence of clubbing has the highest
positive predictive value (75%) and dyspnea the highest
negative predictive value (100%) for hepatopulmonary syn-
drome (HPS). Spider nevi are a common clinical feature of
patients with HPS with a signiﬁcant relationship between
cutaneous spider angiomata and systemic and pulmonary
vasodilatation suggesting that spider nevi may represent a
cutaneous marker for intrapulmonary vascular dilatations.
The main characteristics of HPS are intrapulmonary vascu-
lar vasodilatation, associated with signiﬁcant arteriovenous
shunting (AVS) and hypoxemia. Capillary vasodilatation
is most pronounced at the lung bases, explaining ortho-
doxia and platypnea associated with HPS. V/Q (venti-
lation/perfusion) mismatch appears to be a major event
in the pathogenesis of hypoxemia in HPS as a result of
extensive pulmonary vasodilatation, a decrease in V/Q ratio
in alveolar-capillary units, and resultant low PO2 and O2
contentofblood leavingthe lungs.The defectinoxygenation
isduetopulmonarycapillariesdilatation;oxygenencounters
diﬃculty in diﬀusing into the centre of the larger capillaries.
Increased CO and the associated reduced transition time
of blood through the pulmonary vascular bed also impair
diﬀusion, leading to a diﬀusion-perfusion defect or alveolar
capillary oxygen disequilibrium.
T w ot y p e so fH P Sh a v eb e e nd e s c r i b e d :t y p eIi sa s s o c i -
ated with vascular dilatations at the precapillary level close to
the normal gas exchange units of the lung; type II with focal
larger dilatations amounting to arterial-venous shunting
distant from the gas exchange units.
Supplementary oxygen improves type I HPS PaO2 but
not type 2 HPS [13, 64]. The HPS is associated with
an increased risk of death, and the median survival time
in cirrhotic patients has been reported as 10.6 months
compared to 40.8 months in cirrhotic patients without HPS.
SurvivalisworsewithbaselinePaO2 <50mmHg.Theleading
cause of death is hemorrhagic shock due to gastrointestinal
bleeding [65].
The diagnosis relies on imaging techniques and arterial
gas analysis. The cut-oﬀ values of PaO2 are controversial.
Schenkandcolleagues[66]suggestedthatarterialhypoxemia
deﬁned as a PaO2 <70mmHg or below the age-related
threshold predicted the presence of HPS with high proba-
bility in the absence of intrinsic cardiopulmonary diseases. A
chest radiograph (CXR) and pulmonary function tests must
be used to help exclude other causes of hypoxia such as pul-
monary atelectasis, ascites, chronic obstructive pulmonary
disease, and hepatic hydrothorax.
AdeﬁnitivediagnosisofHPScanbemadebydemonstra-
tion of pulmonary vasodilatation associated with functional
arteriovenous shunting. Imaging studies such as contrast
echocardiography and perfusion scintigraphy with 99mTc
can be used. A simple echocardiography method can also
be used consisting in the injection of 10mL of 0.9% saline;
the normal time of appearance of this “contrast” on the left
heart chambers is 4 heart beats; if the saline is visualized
earlier,itmeansthatarapidtranspulmonarycirculationmay
be present and HPS is suspected [67].
Liver transplantation is the only deﬁnitive treatment for
HPS with at least 85% of patients experiencing signiﬁcant
improvement or complete resolution of hypoxemia follow-
ing surgery; however, these patients have a higher post-
transplant mortality rate. Several therapeutic trials in HPS
have shown poor results such as somatostatin analogues,
cyclooxygenase inhibitors, and immunosuppressive agents
namely corticosteroids and cyclophosphamide [68]. Some
reports have shown improvement in gas exchange with
the use of TIPS in HPS [69]. Mart´ ınez-Pall´ ı et al. [70]i n
another study concluded that TIPS neither improved nor
worsened pulmonary gas exchange in patients with portal
hypertension.6 Critical Care Research and Practice
ESLD patient 
proposed to liver 
transplantation
TTE suggestive of elevated pulmonary artery pressure?
Routine surveillance  Perform right catheterization to establish diagnosis 
Defer liver transplantation if  Consider liver transplantation if
Yes No
Consider mono- or combined vasodilator therapy
• PASP > 40mmHg
TTE every 1-2 years of PoPH:
MPAP > 25mmHg
PVR: > 240dynes s/cm5
PAOP < 15mmHg
TPG > 12mmHg
MPAP > 35mmHg and/or
PVR > 240dyne s/cm5
MPAP < 35mmHg and
PVR < 240dyne s/cm5
￿ Enlarged or dilated right ventricle
￿ Right ventricle dysfunction
Figure 2: Screening and management of Portopulmonary hypertension (Modify of The University of California, San Francisco).
Table 5: Treatment options for hepatopulmonary syndrome.
Prostacyclin analogues
Potent pulmonary and systemic vasodilators
A n t a g o n i s to fp l a t e l e ta g g r e g a t i o n
Epoprostenol is the most commonly used drug in this class, is eﬃcacious, but has several adverse eﬀects
related to safety, tolerability, and route of administration (short half-life, requiring the insertion of
central venous access)
Nebulized iloprost, 6–9 times a day, has shown improved symptoms, exercise tolerance, and functional
capacity
Treprostinil, a stable and long-acting prostacyclin analogue, can be administered subcutaneously and
intravenous
Endothelin antagonist
Bosentan, a nonselective ET-1 receptor antagonist, improves exercise tolerance, functional capacity, and
pulmonary hemodynamics, but also can worsen hepatic dysfunction and deteriorate renal failure
especially in patients with type 2 HRS
Ambrisentan: a selective ETA receptor antagonist, oral and once a day administration, with minimal
hepatotoxicity risk
Phosphodiesterase-5-inhibitors Sildenaﬁl and tadalaﬁl, their use results in an increased NO-mediated vasodilatation in the pulmonary
vasculature
Vasopressin analogues
Terlipressin: several reports have shown that the administration of terlipressin decreases pulmonary
artery pressure in cirrhotic patients with mild pulmonary hypertension, and reduces portal pressure,
improves hyperdynamic circulation and functional renal failure via stimulation of mesenteric V1
receptors [12]Critical Care Research and Practice 7
6. Renal Dysfunction
Renal dysfunction in patients with advanced liver disease
is characterized by increased renal sodium and solute-free
water retention leading to ascites and hyponatremia, renal
vasoconstriction with decreased glomerular ﬁltration rate
(GFR).
The diagnosis of renal failure in patients with cirrhosis is
deﬁned as an increase in serum creatinine 1.5mg/dL, which
corresponds to a GFR of 30mL/min. Other deﬁnitions such
asacutekidneyinjury(AKI)canbeused.AKIisdeﬁnedasan
abrupt (two days) reduction in renal function manifested by
an absolute increase in serum creatinine of at least 0.3mg/dL
or a percentage increase in serum creatinine of more than or
equal to 50% (1.5 fold from baseline) or a urine output of
less 0.5mL/Kg/hour for more than six hours.
New biomarkers of renal function in cirrhosis are
currentlybeingstudiedasmarkersofrenaldiseaseinpatients
with advanced liver disease: neutrophil gelatinase-associated
lipocalin (NGAL) and kidney injury molecule-1 (KIM-1).
One study observed that plasma NGAL and APACHE II were
the most powerful predictors of severe AKI within the ﬁrst 2
days after LT [71].
It is important to remember that there are several causes
of renal failure in cirrhosis: renal failure associated with
infections, hypovolemia-induced renalfailure,intrinsic renal
disease, hepatorenal syndrome, and drug-induced renal fail-
ure.
One study, which included 562 hospitalized patients with
cirrhosisandrenalfailure,foundthatrenalfailurewasassoci-
ated with bacterial infections in 46% of cases, hypovolemia-
induced renal failure in 32%, hepatorenal syndrome in 13%,
parenchymal nephropathy in 9%, and drug-induced renal
failure in 7.5% [72].
Hyponatremia develops in the setting of ascites, and
is associated with poor prognosis hepatic encephalopathy,
especially when serum sodium levels is less than 130mEq/L,
due to changes in serum osmolality that lead to astrocyte
swelling.
Some studies indicate that hyponatremia in post-LT
patients is related to an increased risk of developing renal
failure and bacterial infections during the ﬁrst month after
orthotopic liver transplantation, with a 3-month increased
mortality [73, 74].
7. HepatorenalSyndrome
The hepatorenal syndrome (HRS) refers to the development
of renal failure in a patient who has advanced liver disease.
Signs of portal hypertension, in particular ascites, must be
present; without them, the diagnosis of HRS is compro-
mised. Diagnostic criteria are presented in Table 6.
There are two types of HRS: type 1 is rapidly progressive
with serum creatinine doubling to more than 2.5mg/dL
or a 50% reduction in creatinine clearance to less than
20mL/min in a period of less than 2 weeks. Such patients
may be classiﬁed as oliguric (deﬁned as less than 500mL
of urine per day), but most are nonoliguric at the time of
HRS diagnosis (if oliguria is deﬁned as less than 400mL per
day). This form often occurs in an in-patient setting after
a precipitating event, usually accompanied by concurrent
bacterial infection, gastrointestinal bleeding, recent surgery,
acute hepatitis and signs, and symptoms of severe hepatic
insuﬃciency with jaundice, coagulopathy, encephalopathy,
and circulatory dysfunction [75, 76].
Type 2 is notable for a steady and slow progressive rise
in SCr in an out-patient setting in the cirrhotic patient with
ascites.Theoverallsurvivalrateisabout50%at1monthand
20% at 6 months. Mortality is higher with type 1 HRS than
with type 2 HRS, with a median survival of 2–4 weeks versus
5–6 months, respectively [76].
8. Coagulation Abnormalities
The hemostatic state in patients with severe liver disease may
be considered as a state of reduced capability to maintain the
fragile hemostatic balance. The liver is the site of ﬁbrinogen
factors II, V, VII, IX, XI, XII, and XIII synthesis. Also in
the liver vitamin-K-dependent postribosomal conversion of
glutamic acid residues in the protein precursor to gamma-
carboxyglutamic acid takes place; this is an active process
in the blood coagulation. A failure of carboxylation of
coagulation factors results in an abnormal production of
protein molecules that are nonfunctional [77].
Patients with liver disease and LC have a disturbed
balance of procoagulant and anticoagulant factors charac-
terized by an increased bleeding risk, decreased production
of nonendothelial cell-derived coagulation factors, throm-
bocytopenia, altered platelet function, platelet inhibition by
NO, abnormalities of ﬁbrinogen, and decreased thrombin
activatable ﬁbrinolysis. In severe liver disease there is an
increased concentration of tissue plasminogen activator
due to its decreased hepatic clearance and the decreased
thrombin activatable ﬁbrinolysis inhibitor, as well as a
decreased concentration of alpha-2-antiplasmin. There is
also increased thrombotic risk due to decreased levels of
liver-synthesized proteins C and S, alpha-2-macroglobulin,
andantithrombinIII.Atthesametime levelsofplasminogen
and heparin cofactor II are elevated.
Relative to thrombocytopenia and platelet dysfunction
many theories have arise: decreased level of thrombopoietin,
splenic sequestration of platelets due to portal hypertension,
autoantibody destruction of platelets, and bone marrow
suppression. Platelet dysfunction is also a contributing factor
to decreased clot formation. In addition, patients with
liver disease and concomitant renal insuﬃciency (such as
diﬀerent forms of hepatorenal syndrome) may have platelet
dysfunction due to uremia and due to changes in vessel wall
endothelialfunction.Thisisacommonandoftenoverlooked
aspect of impaired hemostasis in cirrhosis [78].
9. HepaticEncephalopathy Syndrome
In cirrhosis the onset of hepatic encephalopathy is related
to precipitating factors that expose the brain to toxins.
Hyperammonemia is a common feature that occurs due to
the hydrolyzation of ammoniac molecules, which acquire8 Critical Care Research and Practice
Table 6: Diagnostic criteria of hepatorenal syndrome.
Chronic or acute hepatic disease with advanced hepatic failure and portal hypertension.
A plasma creatinine concentration above 1.5mg/dL (133 micromol/L) that progresses over days to weeks.
The absence of any other apparent cause for the renal disease, including shock, ongoing bacterial infection, current or recent treatment
with nephrotoxic drugs, and the absence of ultrasonographic evidence of obstruction or parenchymal renal disease.
Urine red cell excretion of less than 50 cells per high power ﬁeld (when no urinary catheter is in place) and protein excretion less than
500mg/day.
Lack of improvement in renal function after volume expansion with intravenous albumin (1g/kg of body weight per day up to 100g/day)
for at least two days and withdrawal of diuretics.
hydrosolubility, facilitating the accumulation of these dan-
gerous products in the organism.
The increased diﬀusion of ammonia into the brain is
explained by a diminished hepatic clearance and increased
blood-brain barrier permeability. There is an increased
GABAergic tone induced by hyperammonemia, which pro-
duces behavioral disturbances. Parallel to this process the
patients with hepatic encephalopathy show a decreased
consumption of oxygen and glucose.
The ammonia could be related to the inhibition of
cerebral energy metabolism, but it is not clear whether the
decrease in oxygen consumption is the cause or the con-
sequence of encephalopathy. A high lactate/pyruvate ratio
was found in patients with acute liver failure indicating an
impairedbrainenergymetabolismintheabsenceofhypoxia,
an explanation for these ﬁndings could be the inhibition of
limiting steps in the Krebs cycle and compromised oxidative
phosphorylation in the mitochondrial inner membrane;
an excessive glutamatergic activation leads to enhanced
glycolysis with an increased lactate concentration. The West
Haven criteria for hepatic encephalopathy are presented in
Table 7.
The development of brain edema is related to the
intensityanddurationofhyperammonemia,astheincreased
plasma ammonia concentration leads to an increased lactate
concentration that decreases brain pH and causes injury to
the atrocities leading to the accumulation of water in the
intracellular compartment. Hyponatremia may exacerbate
astrocyte swelling due to diﬀerences in osmolality between
the intracellular and the extracellular compartments. In
cirrhosis, hyponatremia is associated with poor short-term
prognosis [79]. The risk of edema is very low in grade 1 to
2 hepatic encephalopathy, and it increases in grade 3 to 25
(35%) and in grade 4 to 65 (75%).
The management of high-grade encephalopathy with
brain edema and intracranial hypertension could be helped
by using neuroimaging techniques and invasive monitoring
of intracranial pressure (ICP). Supportive measures include:
airmway protection; ventilation control and hyperventila-
tion; preservation of adequate cerebral pressure; elevation
of the head of the bed; and osmotic diuresis with mannitol.
The treatment is aimed to reverse precipitating factors such
as gastrointestinal bleeding, excess dietary protein, azotemia,
constipation, hyponatremia, hypokalemia, metabolic distur-
bances, hypoxia, hypovolemia, infection, surgery, transjugu-
lar intrahepatic portosystemic shunt, narcotics, and sedative
drugs.
Thepharmacologicaltherapyforhepaticencephalopathy
is based on the control of ammonia production and uptake
inthegastrointestinaltractandanincreaseinitselimination.
For the reduction of intestinal ammonia production and
absorption nonabsorbable disaccharides like lactulose and
lactitol are the ﬁrst line of therapy for hepatic encephalopa-
thy.
Lactulose mechanism of action is based on its conversion
to organic acid and the consequent acidiﬁcation of the colon,
which results in the suppression of ammoniagenic bacteria
and the conversion of ammonia to ammonium causing a
direct osmotic cathartic eﬀect. The use of oral antibiotics is
under major criticism and is summarized in Table 8.
10. The CardiocirculatoryImpactof
Artiﬁcial Liver Support Systems
Two devices are commercially available in Europe, the
Molecular Adsorption and Recirculating System (MARS),
a technique of albumin dialysis, and fractionated plasma
separation adsorption and dialysis (FPSA), Prometheus, a
technique of detoxiﬁcation. The global objective for these
techniques is to support liver function during periods of
disease exacerbation or acute or chronic liver disease. The
clinical experience has shown that the beneﬁts of these
techniquesarelimited.Also,despitereportsofbettersurvival
in patients waiting for LT [2] ,as y s t e m a t i cr e v i e wo ft h ef e w
available,small,randomizedtrials,bytheCochraneInstitute,
concluded that overall liver support systems did not appear
to aﬀect mortality or eﬀectively bridge patients to LT [80].
Atthistimethereisgreaterknowledgeonthepossibilities
of the artiﬁcial support systems. We know that they are
eﬀective in reducing the serum bilirubin levels, as well
as, in selected patients, in improving encephalopathy. But
several other problems must be mentioned: the propensity
for coagulation abnormalities, a result from the use of non-
fractionated heparin in patients with previously altered
coagulation, and hemodynamic instability.
Few studies evaluated the hemodynamic impact of these
devices. Laleman et al. [81] studied 18 patients and observed
anincreaseinSVRresultinginanincreaseinMAPinpatients
submitted to MARS therapy but not in patients subjected
to Prometheus, thus attenuating the typical hyperdynamic
pattern. Also, in MARS patients a decrease in plasma rennin
activity, aldosterone, vasopressin, and nitrate/nitrite levels
was observed [82]. In our experience we also noticed
that patients submitted to Prometheus are more prone toCritical Care Research and Practice 9
Table 7: The West Haven criteria for hepatic encephalopathy.
Grade 0 Minimal hepatic encephalopathy, no asterixis, and trivial changes in personality or behavior
Grade 1 Trivial lacks of awareness, attention, sleep disturbances, altered mood, and asterixis
Grade 2 Lethargy, apathy, time disorientation, amnesia to recent events, inappropriate behavior, slurred speech, asterixis.
Grade 3 Somnolence, confusion, time and place disorientation, bizarre behaviour, clonus, nystagmus, positive Babinski sign, and
absent asterixis
Grade 4 Coma
Table 8: Oral antibiotics in hepatic encephalopathy.
Neomycin
There are no well-designed studies
Long-term use limited by nephrotoxicity and ototoxicity
Chronic hepatic encephalopathy: 1–4g/day
Acute hepatic encephalopathy: 1–2r every 4–6 hours
Metronidazole
Not approved for hepatic encephalopathy
Side eﬀects: neurotoxicity and gastrointestinal disturbances.
Oral dose: 250mg every 12 hours
Rifaximin
Multiple studies have demonstrated safety and eﬃcacy for the treatment of acute and chronic encephalopathy
Two trials compared rifamixine versus rifamixin with lactulose and lactitiol and suggested that rifamixin produces equal
or superior improvement of ammonia levels and hepatic encephalopathy in shorter time
hypotension. Although this device does not alter the hyper-
dynamic proﬁle, its extracorporeal circuit reaches 900mL; in
the MARS system, this extracorporeal circuit reaches only
150mL. Also, Dethloﬀ et al. [83]o b s e r v e dad e c r e a s ei n
platelet count with the use of Prometheus.
A modiﬁcation in plasma levels of inﬂammatory cytok-
ines was observed in patients subjected to MARS therapy
[84]. There is no data on the long-term eﬀectof these devices
on the cardiocirculatory system.
An improvement in hepatic encephalopathy was ob-
served by some authors [85]. However, despite these ob-
servations, a favourable impact on overall survival with the
use of MARS and/or Prometheus is still lacking [86]. The
experience on the use of liver support devices with biological
components (bioartiﬁcial liver, BAL) is limited.
11. InfectiousProblems in
Patients withLiverCirrhosis
Infections stand amongst the major causes for decompen-
sating liver cirrhosis and contribute towards the mobility
and mortality of these patients. Bacterial infections are
present at admission or develop in approximately 30% of
cirrhotic patients. About 60% of infections are community
acquired and the last 40% are nosocomial. The most com-
mon infections are spontaneous bacterial peritonitis (SBP),
urinarytractinfections,pneumonia,andbacteremiawithout
recognizable focus [87]. Bacteremia without recognizable
focus is 10 times more frequent in liver cirrhosis patients,
and up to 12% of liver cirrhosis patients may experience
it [88, 89]. The most important bacterial agents are Gram-
negative bacteria.
Patients with liver cirrhosis have immune dysfunction,
making them more prone to infection. The recognized
factors involve a decreased bactericidal function of plasma,
decreasedopsonization capacity, impaired macrophageFCγ-
receptor-mediated clearance of antibody-coated bacteria,
downregulation of HLA DR expression and lower comple-
mentlevels,andfunctionalalterationsoftheneutrophils[90,
91]. It is also associated with altered immune function and
cytokine release in response to infection. Zimmerman et al.
[92] showed that alcoholic patients exhibited lower plasma
levels of interleukine 8 (IL8) during the onset of infection;
in septic shock, alcoholic patients presented decreased levels
of IL-1β, IL-6, and IL-8. Other anti-inﬂammatory cytokines,
likeIL-10,andproinﬂammatoryTNFreceptorsdidnotdiﬀer
from cross-matched patients without alcohol intake.
Data from the Cochrane database [93] showed that
mortality due to SBP has improved in the last decade, but
other infections did not, namely, spontaneous bacteriemia
and pneumonia. LC patients are at high risk for the devel-
opment of pulmonary infections [94] .A p a r tf r o mi m m u n o -
logical functions, there other important factors such as
mechanical (reduced lung expansion due to the presence of
ascites), altered mental status and reduced cough reﬂex, and
intoxications. Also, the incidence of severe complications,
such as the adult respiratory distress syndrome (ARDS),
occurs more frequently in LC patients [95]. Viasus et al.
[96] described a series of 90 LC patients with community-
acquired pneumonia, where the most prevalent agents were
Streptococcuspneumoniaand Pseudomonasaeruginosa.These
authors also described that the severity of liver dysfunction,
accessed by the MELD score, was an independent risk factor
for mortality.
Severe sepsis is also more common in cirrhosis patients.
In its initial stages a cytokine storm converts responses that
are usually beneﬁcial into excessive damaging inﬂammation.
Cirrhosis patients present a dual phenomenon: there is an
imbalance in cytokine response and the decompensated liver
disease is characterized by a pattern that closely resembles
the sepsis-associated patterns. Then, the inﬂammatory phase10 Critical Care Research and Practice
is followed by a prolonged compensatory anti-inﬂammatory
response syndrome responsible for nosocomial infections
and increased death rate [90]. On the other hand patients
withlivercirrhosissuﬀerfromcoagulationandliverfunction
abnormalities, situations related or aggravated in severe
sepsis; the vasopressor release is already dysfunctioning due
to the underlying disease. These factors may be responsible
for a more rapid and severe disease, contributing to higher
mortality in the ICU. All pathologic alterations related
to cirrhosis described earlier can eﬀectively contribute to
morbidity and mortality of these patients, and an earlier
detection and intervention must be needed to treat severe
infection in these patients [97–99]. More data is required
for an accurate perception of the outcomes and admission
criteria to the ICU, in order to determine the best prognostic
parameters [100, 101]. The generally accepted rules for
hemodynamic support can be followed [102].
12. Conclusion
The ICU physician must be familiarized with the complex
alterations in physiological systems related to LC. Cardiocir-
culatory dysfunction is present previous to the decompen-
sating end-stage liver disease and is frequently unrecognized.
CCM is a novel clinical condition that can aggravate the
hemodynamic condition and/or support. Although there are
no standard accepted diagnostic methods, echocardiography
can be quite useful. Renal disease and pulmonary disease
are also subject to special conditioning in LC. Diagnostic
criteria for HPS and HRS must be thoroughly observed.
Infectious problems in LC patients are probably the most
life threatening. As the typical events for severe infection
can occur more rapidly, a high detection level and prompt
antibiotherapy must be considered.
Several liver support devices are available, and the ICU
physician must be familiar with their use. All together,
the current care for LC patients requires speciﬁc training
dedicated personnel in a multidisciplinary team, in which
the ICU physician plays a critical role. The connection with a
liver transplantation center is, therefore, mandatory.
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